Labelling of PSMA ligands with positron-emitting radioisotopes which have longer half-lives than 68Ga could be interesting, and Gangemi et al. from Catanzaro, Italy, reported their preliminary experience using 64Cu-PSMA PET/CT in 13 patients with intermediate-risk and high-risk prostate cancer before prostatectomy [40]. The gene discussed is FOLH1; the disease is prostate cancer.